MX2017001656A - Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. - Google Patents
Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.Info
- Publication number
- MX2017001656A MX2017001656A MX2017001656A MX2017001656A MX2017001656A MX 2017001656 A MX2017001656 A MX 2017001656A MX 2017001656 A MX2017001656 A MX 2017001656A MX 2017001656 A MX2017001656 A MX 2017001656A MX 2017001656 A MX2017001656 A MX 2017001656A
- Authority
- MX
- Mexico
- Prior art keywords
- bruton
- tyrosine kinase
- kinase inhibitor
- inhibitor combinations
- inhibitor
- Prior art date
Links
- 229940125814 BTK kinase inhibitor Drugs 0.000 title 1
- 229940124291 BTK inhibitor Drugs 0.000 abstract 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 229960001507 ibrutinib Drugs 0.000 abstract 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000036210 malignancy Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462034997P | 2014-08-08 | 2014-08-08 | |
| US201462082972P | 2014-11-21 | 2014-11-21 | |
| US201462086162P | 2014-12-01 | 2014-12-01 | |
| US201562196251P | 2015-07-23 | 2015-07-23 | |
| PCT/US2015/044095 WO2016022853A1 (en) | 2014-08-08 | 2015-08-06 | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017001656A true MX2017001656A (es) | 2017-07-24 |
Family
ID=55264587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001656A MX2017001656A (es) | 2014-08-08 | 2015-08-06 | Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9730938B2 (OSRAM) |
| EP (1) | EP3177366A4 (OSRAM) |
| JP (1) | JP2017523207A (OSRAM) |
| CN (1) | CN106714909A (OSRAM) |
| AU (1) | AU2015300966A1 (OSRAM) |
| BR (1) | BR112017002232A2 (OSRAM) |
| CA (1) | CA2956550A1 (OSRAM) |
| MX (1) | MX2017001656A (OSRAM) |
| TW (1) | TWI586354B (OSRAM) |
| WO (1) | WO2016022853A1 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101580714B1 (ko) | 2010-06-03 | 2016-01-04 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도 |
| BR112015001690A2 (pt) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
| DK3179991T3 (da) | 2014-08-11 | 2021-12-06 | Acerta Pharma Bv | Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor |
| WO2016071770A2 (en) * | 2014-11-05 | 2016-05-12 | Janssen Pharmaceutica Nv | Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same |
| BR112018074238A2 (pt) | 2016-05-27 | 2019-04-16 | Tg Therapeutics, Inc. | combinação de anticorpo anti-cd20, inibidor de p13 quinase-delta seletivo e inibidor de btk para tratar desordens proliferativas de células b |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| SG10202111394XA (en) | 2017-04-13 | 2021-12-30 | Senti Biosciences Inc | Combinatorial cancer immunotherapy |
| AU2018298855B2 (en) | 2017-07-14 | 2024-07-18 | Janssen Pharmaceutica Nv | Long-acting formulations |
| WO2019070777A2 (en) * | 2017-10-04 | 2019-04-11 | University Of Maryland, Baltimore County | PIM KINASE INHIBITORS IN COMBINATION WITH AUTOPHAGIA INHIBITORS FOR THE TREATMENT OF CANCERS |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
| EP3787751A1 (en) | 2018-05-03 | 2021-03-10 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
| CN111053777A (zh) * | 2018-10-16 | 2020-04-24 | 正大天晴药业集团股份有限公司 | 伊布替尼的药物组合物及其应用 |
| US11419898B2 (en) | 2018-10-17 | 2022-08-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| JP2022512766A (ja) | 2018-10-17 | 2022-02-07 | センティ バイオサイエンシズ インコーポレイテッド | 組み合わせがん免疫療法 |
| HRP20241309T1 (hr) * | 2019-01-09 | 2025-01-03 | Celgene Corporation | Antiproliferativni spojevi i druga aktivna sredstva za upotrebu u liječenju multiplog mijeloma |
| AU2020226723B2 (en) | 2019-02-22 | 2025-01-23 | Janssen Pharmaceutica Nv | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)- |
| US12404260B2 (en) | 2019-04-11 | 2025-09-02 | Janssen Pharmaceutica Nv | Pyridine rings containing derivatives as MALT1 inhibitors |
| EP3871665B1 (en) | 2020-02-28 | 2025-12-24 | Martin-Luther-Universität Halle-Wittenberg | Inhibitors of rna-binding proteins as anti-cancer drugs |
| EP4114378A1 (en) * | 2020-03-05 | 2023-01-11 | Université de Lausanne | Modulators of aralar for treating neurological disorders |
| BR112023000220A2 (pt) * | 2020-07-09 | 2023-01-31 | Janssen Pharmaceutica Nv | Formulações de longa ação |
| BR112023003106A2 (pt) * | 2020-08-21 | 2023-04-04 | Janssen Pharmaceutica Nv | Forma amorfa de um inibidor de malt1 e formulações do mesmo |
| EP3967307A1 (en) * | 2020-09-15 | 2022-03-16 | Instytut Hematologii I Transfuzologii | Use of pim kinase inhibitors to augment the efficacy of anti-cd20 antibody-based therapies in hematologic malignancies and non-malignant conditions |
| CN114469949A (zh) * | 2020-10-27 | 2022-05-13 | 正大天晴药业集团股份有限公司 | 用于治疗弥漫大b细胞淋巴瘤的喹啉衍生物 |
| EP4301365A1 (en) * | 2021-03-03 | 2024-01-10 | Janssen Pharmaceutica NV | Combination therapy using a malt1 inhibitor and a btk inhibitor |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11807689B1 (en) | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| TW202515550A (zh) * | 2023-06-29 | 2025-04-16 | 大陸商上海翰森生物醫藥科技有限公司 | 三并環類抑制劑與抗癌劑在製備抗腫瘤藥物中的聯合應用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6113898A (en) * | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| US7832117B2 (en) * | 2006-07-17 | 2010-11-16 | Nike, Inc. | Article of footwear including full length composite plate |
| DK2529622T3 (en) | 2006-09-22 | 2018-05-07 | Pharmacyclics Llc | INHIBITORS OF BRUTON-TYROSINKINASE |
| DK2185698T3 (en) * | 2007-08-07 | 2015-07-27 | Purdue Research Foundation | Kinase Inhibitors and Uses thereof |
| KR101580714B1 (ko) | 2010-06-03 | 2016-01-04 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도 |
| KR20230109775A (ko) * | 2011-10-19 | 2023-07-20 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(btk)의 억제제의 용도 |
| KR20250151610A (ko) * | 2012-06-04 | 2025-10-21 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| EP2872161B1 (en) | 2012-06-26 | 2020-12-16 | Del Mar Pharmaceuticals | Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
-
2015
- 2015-08-06 EP EP15829601.2A patent/EP3177366A4/en not_active Withdrawn
- 2015-08-06 CA CA2956550A patent/CA2956550A1/en not_active Abandoned
- 2015-08-06 JP JP2017505609A patent/JP2017523207A/ja active Pending
- 2015-08-06 BR BR112017002232A patent/BR112017002232A2/pt not_active Application Discontinuation
- 2015-08-06 CN CN201580047327.7A patent/CN106714909A/zh active Pending
- 2015-08-06 WO PCT/US2015/044095 patent/WO2016022853A1/en not_active Ceased
- 2015-08-06 MX MX2017001656A patent/MX2017001656A/es unknown
- 2015-08-06 AU AU2015300966A patent/AU2015300966A1/en not_active Abandoned
- 2015-08-06 US US14/820,434 patent/US9730938B2/en active Active
- 2015-08-07 TW TW104125847A patent/TWI586354B/zh not_active IP Right Cessation
-
2017
- 2017-07-21 US US15/656,394 patent/US20180071295A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015300966A1 (en) | 2017-02-16 |
| JP2017523207A (ja) | 2017-08-17 |
| CN106714909A (zh) | 2017-05-24 |
| US20160038495A1 (en) | 2016-02-11 |
| US9730938B2 (en) | 2017-08-15 |
| BR112017002232A2 (pt) | 2018-07-24 |
| EP3177366A4 (en) | 2018-04-04 |
| TW201609107A (zh) | 2016-03-16 |
| WO2016022853A1 (en) | 2016-02-11 |
| TWI586354B (zh) | 2017-06-11 |
| US20180071295A1 (en) | 2018-03-15 |
| CA2956550A1 (en) | 2016-02-11 |
| EP3177366A1 (en) | 2017-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017001656A (es) | Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. | |
| MY205416A (en) | Tyk2 inhibitors and uses thereof | |
| MX2017006464A (es) | Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton. | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| CO2018009275A2 (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub) | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| MX2021013118A (es) | Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton. | |
| ZA201708667B (en) | Tyrosine kinase inhibitors | |
| MX2020003939A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos. | |
| MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
| MY199705A (en) | Heterocyclic compounds as immunomodulators | |
| PH12018501084A1 (en) | Heterocyclic compounds as immunomodulators | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| SG10201902326XA (en) | Mk2 inhibitors and uses thereof | |
| MX2022006768A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
| MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| MA43650B1 (fr) | Formulations/compositions comprenant un inhibiteur de btk | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| EP4289820A3 (en) | Compounds for use in treating alzheimer's disease in apoe4+/+ patients | |
| WO2015123449A3 (en) | Compositions and methods of using microrna inhibitors | |
| MY201580A (en) | Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor | |
| MX2019011116A (es) | Inhibidores de la tirosina quinasa de bruton. | |
| MX2018001369A (es) | Combinaciones de inhibidores de tirosina quinasa de bruton y sus usos. |